Wuxi Bios Drug Substance And Drug Product Facilities Receives European And Us Fda Approvals
Wuxi Biologics (Wuxi Bio), A Leading Global Contract Research, Development And Manufacturing Organization, Announced That Its Two Drug Substance (Ds) Facilities And A Drug Product (Dp) Facility Located In Wuxi City Received Regulatory Approvals From The European Medicines Agency (Ema) And The Us Food And Drug Administration (Fda).After Passing Online Pre-Approval Inspection (Pai), Wuxi Biologics Received Ema Gmp Certificates For The Commercial Manufacturing Of Two Biologics Developed By Global Clients At Its Mfg4, Mfg5 And Dp2 Facilities. This Is The First Time Mfg5, The Newest Operational Ds Facility With A Total Of 60,000L Capacity, And Dp2, The Second Dp Facility For Vials, Have Been Certified By The Ema, Only 10 Months After They Were Released For Gmp Manufacturing. The Us Fda Also Approved Mfg5 To Manufacture An Innovative Product For A Global Client.Dr. Chris Chen, Ceo Of Wuxi Biologics, Commented,
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!